APEX Ventures
VC Fund
Vienna, Austria
APEX Ventures is an early-stage venture capital fund that invests in start-ups grounded in unique and protectable technology. They provide support and resources and aims to develop their start-ups in their respective field. Their initial focus areas include digital media, business intelligence, cybersecurity, fintech, and the future of work.
- Total investments:
- 62
- Last investment:
- Lead investor:
- 29%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries APEX Ventures invests in
Stages APEX Ventures invests in
Countries APEX Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Seed
- $1.4M–$8M
- Pre-Seed
- $552k–$9.1M
- Series A
- $5.7M–$28M
Investment Focus
Industry
- Artificial Intelligence 11 (18%)
- Software 10 (16%)
- Health Care 9 (15%)
- Biotechnology 7 (11%)
- Machine Learning 7 (11%)
Stage
- Seed 30 (48%)
- Series A 9 (15%)
- Pre-Seed 5 (8%)
- Funding Round 2 (3%)
- Venture - Series Unknown 2 (3%)
Country
- Germany 14 (23%)
- United Kingdom 9 (15%)
- Austria 8 (13%)
- Spain 2 (3%)
- United States 2 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andreas Riegler
General Partner
|
General Partner | Total investments: 3 | Find email | |
Christoph Kanneberger
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 4 | Find email | |
Stefan Haubner
Founding Partner & General Partner
|
Founding Partner & General Partner | Total investments: 1 | Find email | |
Diana Röttger
Principal
|
Principal | Total investments: 1 | Find email | |
Jon M. Van Winkle
Principal
|
Principal | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early detection and prediction of pregnancy complications, particularly preeclampsia. | $17.4M / Seed / Sep 02, 2026 | ||
| Jago Coffee serves freshly brewed coffee beverages wherever you are through a fleet of fully electric mobile cafes. | $12.5M / Series B / Feb 03, 2026 | ||
| Quibim, with headquarters in Valencia, Spain, is a global leader in whole-body medical imaging analysis. Quibim products are used worldwide by leading pharmaceutical companies and research teams. Partners use Quibim Precision®, a whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy ofnovel treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers. We understand every body part. We speak human. | $50M / Series A / Jan 28, 2025 | ||
| Robeaute is a research and development agency that develops neurosurgical microrobots that can adapt to different types of medical evidence. | $28M / Series A / Jan 14, 2025 | ||
| HyperHeat is building a cutting-edge, all-electric heating solution designed to reach temperatures of up to 2,000°C. Using renewable electricity HyperHeat is providing an efficient alternative to fossil fuel combustion. With an efficiency rate of up to 98%, HyperHeat is ideal for retrofitting industrial processes, enabling significant CO2reductions across industries like steel, cement, and chemicals. The scalable technology offers a cost-efficient approach to decarbonizing thermal processes, with a potential to reduce global CO2 emissions by over 4.5 gigatons annually. | $3.1M / Pre-Seed / Nov 26, 2024 | ||
| Gemesys creates a chip that functions similarly to the human brain in order to overcome processing constraints and empower AI with the hardware it needs to complete its destiny | $9.1M / Pre-Seed / Nov 19, 2024 | ||
| TriLite Technologies is a developing world display tech for AR/VR applications. | $22M / Series A / Sep 11, 2024 | ||
| CardiaTec is a TechBio business that uses computational tools to unravel the biology underlying cardiovascular illness. CardiaTec uses massive and high-dimensional human omics data to better understand complicated disease biology and identify novel and differentiated therapies. | $6.5M / Seed / Sep 10, 2024 | ||
| Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $4.8M / Mar 18, 2024 | ||
| Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $4.7M / Seed / Mar 18, 2024 | ||
| See all 62 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does APEX Ventures invest in?
APEX Ventures invests primarily in Artificial Intelligence, Software and Health Care startups, most often at Seed and Series A stage. Most of the 62 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is APEX Ventures's check size?
APEX Ventures typically joins rounds of $1.4M–$8M at Seed, $552k–$9.1M at Pre-Seed and $5.7M–$28M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds APEX Ventures participates in.
How do I contact APEX Ventures?
Public channels for APEX Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at APEX Ventures?
The team at APEX Ventures includes Andreas Riegler (General Partner), Christoph Kanneberger (Founder & Managing Partner) and Stefan Haubner (Founding Partner & General Partner), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
